Mariam Allbee‐Johnson

Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy

Santiago Mercadal, Kwang Woo Ahn, Mariam Allbee‐Johnson, Siddhartha Ganguly et autres

us (code pays fourni par la source)

Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry

Rachel Cusatis, Carlos Litovich, Zhongyu Feng, Mariam Allbee‐Johnson et autres

The Center for International Blood and Marrow Transplant Research (CIBMTR) prepares an annual set of summary slides to summarize the trends in transplantation and cellular therapies. For the first time in the 2023 summary slides, the CIBMTR incorporated data for patients receiving …

us (code pays fourni par la source)

Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient Outcomes

Yung‐Tsi Bolon, Rasha Atshan, Mariam Allbee‐Johnson, Noel Estrada-Merly et autres

Hematopoietic cell transplantation (HCT) has undergone many advances over the decades. Trends in HCT utilization have been impacted by research based on the data and samples collected by the Center for International Blood and Marrow Transplant Research (CIBMTR). Here, we provide a …

us (code pays fourni par la source)

Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis

Narendranath Epperla, Hamza Hashmi, Kwang Woo Ahn, Mariam Allbee‐Johnson et autres

Data will be available on the CIBMTR public website. Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the …

us (code pays fourni par la source)

Outcomes of Large B-Cell Lymphoma (LBCL) Patients with Secondary Central Nervous System Involvement Following Chimeric Antigen Receptor T-Cell Therapy: A CIBMTR Analysis

Hamza Hashmi, Narendranath Epperla, Kwang Woo Ahn, Mariam Allbee‐Johnson et autres

Chimeric antigen receptor T-cell (CAR-T) therapy is a standard treatment option for patients (pts) with relapsed and refractory large B cell lymphoma (LBCL). Outcomes in pts with LBCL with secondary CNS involvement (SCNSL) are poor and treatment options are limited. There are …

us (code pays fourni par la source)

CD19-Directed CART Therapy for T Cell/Histiocyte Rich Large B-Cell Lymphoma: A CIBMTR Analysis

Joshua Fein, Priyanka A. Pophali, Kwang Woo Ahn, Mariam Allbee‐Johnson et autres

T cell/Histiocyte Rich Large B-cell Lymphoma (THRLBCL) is a rare histologic variant of large B-cell lymphoma (LBCL) with less favorable treatment outcomes. While CD19-directed chimeric antigen receptor T-cell (CART) therapy is effective in large B-cell lymphoma, its role in THRLBCL is controversial. …

us (code pays fourni par la source)

Social Disparities and Cancer: The Biologic Fingerprint of Stress is Transplantable and Associated with Worse Clinical Outcomes

Jennifer M. Knight, Steve W. Cole, Kirsten Beyer, Tao Wang et autres

us (code pays fourni par la source)

Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation

Jennifer M. Knight, Steven W. Cole, Kirsten Beyer, Tao Wang et autres

us (code pays fourni par la source)

Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation

Jennifer M. Knight, Steven W. Cole, Kirsten Beyer, Tao Wang et autres

us (code pays fourni par la source)

Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation.

Jennifer M. Knight, Steve W. Cole, Kirsten Beyer, Tao Wang et autres

6500 Background: Allogeneic hematopoietic cell transplantation (HCT) carries significant risks, with low socioeconomic status (SES) being predictive of increased mortality. Our team recently discovered that socioeconomic disadvantage among unrelated HCT donors results in decreased recipient overall survival (OS) and increased treatment-related mortality …

us (code pays fourni par la source)

Late Graft Failure in MDS and Acute Leukemia Patients Receiving Allogenic Hematopoietic Cell Transplantation with Post Transplant Cyclophosphamide As Gvhd Prophylaxis

Cindy Lynn Hickey, Mei‐Jie Zhang, Mariam Allbee‐Johnson, Rizwan Romee et autres

Introduction: Post-transplant cyclophosphamide (PTCy) is a commonly used prophylactic therapy for graft-vs-host disease (GVHD), particularly in the setting of haploidentical (haplo) transplantation. Despite prior studies showing comparable survival outcomes when compared to HLA matched unrelated donor transplantation (MUD-HCT) using traditional calcineurin inhibitor …

us (code pays fourni par la source)

Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation

Sagar S. Patel, Kwang Woo Ahn, Manoj Khanal, Caitrin Bupp et autres

Noninfectious pulmonary toxicity (NPT), a significant complication of allogeneic hematopoietic cell transplantation (alloHCT), includes idiopathic pneumonia syndrome (IPS), diffuse alveolar hemorrhage (DAH), and cryptogenic organizing pneumonia (COP), with an overall incidence ranging from 1% to 15% in different case series and a …

us, jo, nz, jp (code pays fourni par la source)